Autolus Therapeutics is classified as a low-priced equity or small-cap biotechnology stock, trading at single-digit share prices. While its share price range often places it colloquially near micro-cap or low-priced thresholds, it is a major clinical-stage enterprise listed on the Nasdaq Global Select Market with institutional backing, rather than an unlisted micro-cap OTC penny stock.